Related references
Note: Only part of the references are listed.Androgen receptor agonists as breast cancer therapeutics
Jennifer L. Caswell-Jin et al.
NATURE MEDICINE (2021)
Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis
Carson A. Wills et al.
CANCER RESEARCH (2021)
Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer
Stephanie Metcalf et al.
CLINICAL & EXPERIMENTAL METASTASIS (2020)
Parallel Reaction Monitoring-Mass Spectrometry (PRM-MS)-Based Targeted Proteomic Surrogates for Intrinsic Subtypes in Breast Cancer: Comparative Analysis with Immunohistochemical Phenotypes
Joonho Park et al.
JOURNAL OF PROTEOME RESEARCH (2020)
SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation
Peiyuan Zhang et al.
NATURE COMMUNICATIONS (2020)
Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer
Chuqian Lei et al.
JOURNAL OF BREAST CANCER (2020)
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98
Kevin H. Kensler et al.
BREAST CANCER RESEARCH (2019)
Long pentraxin 3: A novel multifaceted player in cancer
Arianna Giacomini et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages
Olivia Ihedioha et al.
IMMUNOLOGIC RESEARCH (2018)
Loss of TRIM29 Alters Keratin Distribution to Promote Cell Invasion in Squamous Cell Carcinoma
Teruki Yanagi et al.
CANCER RESEARCH (2018)
Expression of proliferation genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast carcinomas. Feasibility and relevance for a routine histopathology laboratory
Carla Thomas et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics
Christopher E. Barbieri et al.
EUROPEAN UROLOGY (2017)
The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin
Margarida M. Bernardo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2017)
PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer
Song Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Cancer heterogeneity determined by functional proteomics
A. Marcell Szasz et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Jose Luis Perez-Gracia et al.
CANCER TREATMENT REVIEWS (2017)
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Daniel V. T. Catenacci et al.
GASTRIC CANCER (2016)
Postovulatory aging affects dynamics of mRNA, expression and localization of maternal effect proteins, spindle integrity and pericentromeric proteins in mouse oocytes
T. Trapphoff et al.
HUMAN REPRODUCTION (2016)
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
Paolo Nuciforo et al.
MOLECULAR ONCOLOGY (2016)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers
Manuel Scimeca et al.
TUMOR BIOLOGY (2016)
Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature
Marwa Matboli et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Clinical implications of molecular heterogeneity in triple negative breast cancer
Brian D. Lehmann et al.
BREAST (2015)
Targeted Therapies in Triple-Negative Breast Cancer
Frederik Marme et al.
BREAST CARE (2015)
Altered intracellular region of MUC1 and disrupted correlation of polarity-related molecules in breast cancer subtypes
Misato Iizuka et al.
CANCER SCIENCE (2015)
Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues
Carine Steiner et al.
MOLECULAR & CELLULAR PROTEOMICS (2015)
Role of the Tumor Microenvironment in Breast Cancer
Savas D. Soysal et al.
PATHOBIOLOGY (2015)
Characterization of a human pluripotent stem cell-derived model of neuronal development using multiplexed targeted proteomics
Tom Dunkley et al.
PROTEOMICS CLINICAL APPLICATIONS (2015)
The role of taxanes in triple-negative breast cancer: literature review
Giorgio Mustacchi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
TRIM29 Suppresses TWIST1 and Invasive Breast Cancer Behavior
Lingbao Ai et al.
CANCER RESEARCH (2014)
Panorama: A Targeted Proteomics Knowledge Base
Vagisha Sharma et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer
Ning Qing Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry- based Assay Development Using a Fit- for- Purpose Approach
Steven A. Carr et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Tissue Specific DNA Methylation in Normal Human Breast Epithelium and in Breast Cancer
Ayelet Avraham et al.
PLOS ONE (2014)
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
Daniel V. T. Catenacci et al.
PLOS ONE (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
The proteomics of formalin-fixed wax-embedded tissue
David Cilia Vincenti et al.
CLINICAL BIOCHEMISTRY (2013)
Proteomic studies of formalin-fixed paraffin-embedded tissues
Laura Giusti et al.
EXPERT REVIEW OF PROTEOMICS (2013)
Therapeutic targets in triple negative breast cancer
Sandra A. O'Toole et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue
Todd Hembrough et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard
Jennifer R. Won et al.
MODERN PATHOLOGY (2013)
TRIM29 Functions as a Tumor Suppressor in Nontumorigenic Breast Cells and Invasive ER+ Breast Cancer
Jin Liu et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Triple-negative breast cancer in the older population
P. Boyle
ANNALS OF ONCOLOGY (2012)
Precision of Multiple Reaction Monitoring Mass Spectrometry Analysis of Formalin-Fixed, Paraffin-Embedded Tissue
Robert W. Sprung et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Highly multiplexed targeted proteomics using precise control of peptide retention time
Sebastien Gallien et al.
PROTEOMICS (2012)
Using iRT, a normalized retention time for more targeted measurement of peptides
Claudia Escher et al.
PROTEOMICS (2012)
Triple-negative and basal-like breast cancer: implications for oncologists
J. Lachapelle et al.
Current Oncology (2011)
Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer
Yoshihisa Umekita et al.
DIAGNOSTIC PATHOLOGY (2011)
Selected reaction monitoring applied to proteomics
Sebastien Gallien et al.
JOURNAL OF MASS SPECTROMETRY (2011)
Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches
Angelo Gamez-Pozo et al.
MOLECULAR BIOSYSTEMS (2011)
A clinically relevant gene signature in triple negative and basal-like breast cancer
Achim Rody et al.
BREAST CANCER RESEARCH (2011)
Effect of Collision Energy Optimization on the Measurement of Peptides by Selected Reaction Monitoring (SRM) Mass Spectrometry
Brendan MacLean et al.
ANALYTICAL CHEMISTRY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
Clare G. Fedele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
High expression of maspin is associated with early tumor relapse in breast cancer
Kristiina M. Joensuu et al.
HUMAN PATHOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genome-specific gas-phase fractionation strategy for improved shotgun proteomic profiling of proteotypic peptides
Alexander Scherl et al.
ANALYTICAL CHEMISTRY (2008)
Subtypes of breast cancer show preferential site of relapse
Marcel Smid et al.
CANCER RESEARCH (2008)
Selected reaction monitoring for quantitative proteomics: a tutorial
Vinzenz Lange et al.
MOLECULAR SYSTEMS BIOLOGY (2008)
Triple negative tumours: a critical review
J. S. Reis-Filho et al.
HISTOPATHOLOGY (2008)
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma
B. van der Vegt et al.
HISTOPATHOLOGY (2007)
Opinion - Shaping the future of biomarker research in breast cancer to ensure clinical relevance
M. Carolina Hinestrosa et al.
NATURE REVIEWS CANCER (2007)
Mass spectrometric analysis of formalin-fixed paraffin-embedded tissue: Unlocking the proteome within
Brian L. Hood et al.
PROTEOMICS (2006)
Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?
JD Brenton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer
EA Rakha et al.
MODERN PATHOLOGY (2005)
Expression of maspin is up-regulated during the progression of mammary ductal carcinoma
Y Umekita et al.
HISTOPATHOLOGY (2003)
Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer
DH Kim et al.
HISTOPATHOLOGY (2003)
Expression of maspin predicts poor prognosis in breast cancer patients
Y Umekita et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Extracellular matrix components in breast carcinomas
A Kadar et al.
SEMINARS IN CANCER BIOLOGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
